Royal Bank Of Canada Pds Biotechnology Corp Transaction History

Royal Bank Of Canada

$479 Billion
Q4 2024

A detailed history of Royal Bank Of Canada transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Royal Bank Of Canada holds 1,490 shares of PDSB stock, worth $1,758. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,490

Previous 2,592 42.52%

Holding current value

$1,758

Previous $9,000 77.78%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$1.63 - $4.11 $1,796 - $4,529	-1,102 Reduced 42.52%	1,490 $2,000
Q3 2024 Nov 14, 2024	SELL	$2.93 - $4.23 $26,416 - $38,137	-9,016 Reduced 77.67%	2,592 $9,000
Q2 2024 Aug 14, 2024	BUY	$2.55 - $4.02 $21,998 - $34,680	8,627 Added 289.4%	11,608 $34,000
Q1 2024 Nov 05, 2024	SELL	$3.85 - $6.59 $33,213 - $56,851	-8,627 Reduced 74.32%	2,981 $11,000
Q1 2024 May 15, 2024	SELL	$3.85 - $6.59 $31,392 - $53,734	-8,154 Reduced 73.23%	2,981 $11,000
Q4 2023 Feb 14, 2024	BUY	$3.95 - $6.58 $20,935 - $34,874	5,300 Added 90.83%	11,135 $55,000
Q3 2023 Nov 14, 2023	BUY	$4.8 - $6.4 $18,484 - $24,646	3,851 Added 194.1%	5,835 $29,000
Q2 2023 Aug 14, 2023	BUY	$5.03 - $9.9 $8,722 - $17,166	1,734 Added 693.6%	1,984 $9,000
Q4 2022 Feb 14, 2023	SELL	$3.28 - $13.2 $6 - $26	-2 Reduced 0.79%	250 $3,000
Q3 2022 Nov 14, 2022	BUY	$2.97 - $5.79 $5 - $11	2 Added 0.8%	252 $1,000
Q2 2022 Aug 15, 2022	SELL	$3.05 - $6.68 $3,574 - $7,828	-1,172 Reduced 82.42%	250 $1,000
Q1 2022 May 16, 2022	BUY	$4.78 - $8.43 $4,383 - $7,730	917 Added 181.58%	1,422 $9,000
Q4 2021 Feb 14, 2022	BUY	$7.76 - $14.35 $3,918 - $7,246	505 New	505 $4,000

Others Institutions Holding PDSB

# of Institutions

Shares Held

4.22M

Call Options Held

170K

Put Options Held

6.7K

View Full List

About PDS Biotechnology Corp

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $33.6M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

More about PDSB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Pds Biotechnology Corp Transaction History